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Martin C. Taylore, John M. Kellye and Silvana Raic-Malicb
aFaculty of Textile Technology, Department of Applied Chemistry, University of Zagreb, Zagreb, Croatia; bFaculty of Chemical Engineering and
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Croatia; dDivision of Organic Chemistry and Biochemistry, Rud-er Boskovic Institute, Zagreb, Croatia; eDepartment of Infection Biology, London
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ABSTRACT
A series of 6-amidinobenzothiazoles, linked via phenoxymethylene or directly to the 1,2,3-triazole ring
with a p-substituted phenyl or benzyl moiety, were synthesised and evaluated in vitro against four human
tumour cell lines and the protozoan parasite Trypanosoma brucei. The influence of the type of amidino
substituent and phenoxymethylene linker on antiproliferative and antitrypanosomal activities was
observed, showing that the imidazoline moiety had a major impact on both activities. Benzothiazole imi-
dazoline 14a, which was directly connected to N-1-phenyl-1,2,3-triazole, had the most potent growth-
inhibitory effect (IC50 ¼ 0.25mM) on colorectal adenocarcinoma (SW620), while benzothiazole imidazoline
11b, containing a phenoxymethylene linker, exhibited the best antitrypanosomal potency (IC90 ¼
0.12mM). DNA binding assays showed a non-covalent interaction of 6-amidinobenzothiazole ligands, indi-
cating both minor groove binding and intercalation modes of DNA interaction. Our findings encourage
further development of novel structurally related 6-amidino-2-arylbenzothiazoles to obtain more selective
anticancer and anti-HAT agents.
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The benzothiazoles are constituents of bioactive heterocyclic com-
pounds that exhibit a wide spectrum of biological activities1–5.
Electron deficient, bivalent sulphur atoms in sulphur-containing
heterocycles were found to participate in attractive nonbonding
sulphur aromatic and sulphur halogen interactions that proved to
enhance drug target binding affinity6. Functionalization of the
benzothiazole scaffold at the C-2 and C-6 positions has been a
key determinant for their enhanced biological activity, mainly anti-
proliferative and antiparasitic7–11. Thus, the antiproliferative activ-
ity of amidino- and amino-substituted 2-phenylbenzothiazole
derivatives strongly depended on the position of the substituent
in the benzothiazole skeleton, as well as on the type of amidino
unit12–16. Anticancer effects of 2-arylbenzothiazoles involved meta-
bolic activation by cytochrome P450 to electrophilic reactive spe-
cies, which generated DNA adducts in sensitive tumour cells17.
Polyhydroxylated 2-phenylbenzothiazoles were developed as sur-
rogates for the naturally occurring bioactive flavonoid and isofla-
vone18. Among C-2-arylbenzothiazoles, amino-substituted
derivatives possessed excellent cytotoxicity in nanomolar concen-
trations against several breast cancer cell lines19,20. While the
methylated analogue of C-2-arylbenzothiazole demonstrated
superior in vivo efficacy, albeit, with metabolic instability, the fluo-
rinated analogue exhibited enhanced stability with limited bio-
availability17. The prodrug concept led to the development of the
phortress compound, which had potent antitumor activity against
human mammary tumour xenografts and is in clinical trials for the
treatment of solid tumours21. 2-Piperazinyl benzothiazole deriva-
tives were found to strongly inhibit the growth of hepatocellular,
breast, and colorectal cancer cells22. Even though a number of
structurally related benzothiazoles have been reported to exert
antitumor effect, their mechanism is not fully evaluated, as a prel-
ude to lead optimisation and clinical development. Some benzo-
thiazole-based anticancer agents were found to target tyrosine
kinase, topoisomerase, microtubule, cytochrome P450, heat shock
protein 90 (Hsp90), epidermal growth factor receptor (EGFR) and
apoptosis by activation of reactive oxygen species (ROS)2,23–29.
Amidino benzothiazoles that exhibited strong antiproliferative
activity also exerted good DNA binding affinity having both helix
groove binding and DNA intercalation properties30. Some benzo-
thiazole sulphonamides were found to have a crucial role in the
inhibition of the metalloenzyme carbonic anhydrase (CA IX and
XII) that is overexpressed in hypoxic tumours1,31,32.
Human African trypanosomiasis (HAT,) or sleeping sickness, is
a neglected tropical disease (NTD) caused by Trypanosoma brucei,
a protozoan parasite transmitted to humans through the bite of a
blood-sucking tsetse fly33,34. The drugs currently used to treat
HAT are not effective against all stages and subspecies of the
parasite, so further clinical investigation is needed to develop new
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antitrypanosomal drugs. Some 2-benzylsulfanyl- and 2-arylbenzo-
thiazole derivatives have been found to exhibit good trypanocidal
activity at low concentrations35,36. Optimisation of anti-parasite
activity, physicochemical parameters and ADME properties
afforded the fluoro-substituted benzothiazole, with a 2-cyclopro-
panecarboxamide at position 2, which displayed promising
in vivo efficacy37.
In continuation of our recent work on the development of aro-
matic benzimidazole amidines as antitrypanosomal38–40 and cyto-
static agents41, we have now synthesised new chemical entities
by the fusion of benzothiazole through a phenoxymethylene unit,
or directly to 1,2,3-triazole ring with a p-substituted phenyl or
benzyl subunit (Figure 1).
In this context, the influence of linkers and the type of amidino
substituents of the benzothiazole derivatives 10a–10d, 11a–11d,
12a–12d, 13a–13d, 14a–14d, 15a–15d on their antiproliferative
and antiprotozoal activity has been explored. Compounds with
potent antiproliferative and antitrypanosomal activities were
selected for further investigation of their DNA binding affinities by




Melting points were determined by means of Original Kofler
Mikroheitztisch apparatus (Reichert, Wien). 1H NMR and 13C NMR
spectra were recorded with the Bruker Avance DPX-300 or Bruker
AV-600 using TMS as an internal standard. Chemical shifts are
reported in parts per million (ppm) relative to TMS. UPLC-MS spec-
tra were recorded with Agilent 1290 Infiniti II/6120 Quadruple LC/
MS spectrometers using electrospray ionisation (ESI). Elemental
analyses for carbon, hydrogen, and nitrogen were performed on a
Perkin-Elmer 2400 elemental analyser. Analyses are indicated as
symbols of elements, and the analytical results obtained are
within 0.4% of the theoretical value.
Experimental procedures for the synthesis of compounds
Synthesis of main precursors for the synthesis of targeted benzo-











hyde (6c)42, 1-benzyl-1H-1,2,3-triazole-4-carbaldehyde (6d)43, 2-
amino-5-amidiniumbenzenethiolate (7)45, 2-amino-5-(4,5-dihydro-
1H-imidazol-3-ium-2-yl)benzenethiolate hydrate (8)45 and 2-amino-
5-(3,4,5,6-tetrahydropyrimidin-1-ium-2-yl)benzenethiolate (9)46 was
carried out according to the previously published experimen-
tal procedures.
General method for preparation of compounds 10a–10d,
11a–11d, 12a–12d, 13a–13d, and 14a–14d
To a stirred solution of a corresponding 5-amidino-substituted-2-
amino-benzenethiolate (7–9) (0.25 or 0.5mmol) in glacial acetic
acid (5ml), a corresponding carbaldehyde 3a–3d or 6a–6d (0.25
or 0.5mmol) was added under a nitrogen atmosphere and heated
to reflux for 2–4 h. The reaction mixture was poured onto ice and
made alkaline with 20% NaOH. The resulting free base was fil-
tered, washed with water, and dried. The crude free base was con-
verted into a methanesulfonate salt as described below.
6-Amidinium-2-[(1-phenyl-1H-1,2,3-triazol-4-yl)methoxy]benzothia-
zole methanesulfonate (10a)
According to the above-mentioned general method, 4-[(1-phenyl-
1H-1,2,3-triazol-4-yl)methoxy]benzaldehyde 3a (70mg, 0.25mmol)
Figure 1. Design and synthesis of benzothiazoles with amidines as the hydrophilic end, and an aromatic unit at the N-1 position of the 1,2,3-triazole ring, as the
hydrophobic end.
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and 2-amino-5-amidiniumbenzenethiolate 7 (42mg, 0.25mmol)
were used and refluxed for 4 h, giving 78mg (0.183mmol) of
crude free base. Afterwards, the obtained free base was sus-
pended in ethanol (5ml) followed by the addition of methanesul-
fonic acid (13ml, 0.2mmol) and stirring at room temperature for
2 h. The reaction mixture was cooled overnight, the resulting pre-
cipitate was filtered off and dried at 75 C. Yield of pure com-
pound 10a as colourless solid was 60mg (46.2%), mp ¼
272–275 C. 1H NMR (300MHz, DMSO-d6) d¼ 9.35 (s, 2H,
-C(NH2)2
þ), 8.99 (s, 2H, -C(NH2)2
þ), 8.95 (s, 1H, Ar-H), 8.63 (s, 1H,
Ar-H), 8.21 (d, 1H, J¼ 8.5 Hz, Ar-H), 8.14 (d, 2H, J¼ 8.7 Hz, Ar-H),
7.93–7.90 (m, 3H, Ar-H), 7.64–7.49 (m, 3H, Ar-H), 7.32 (d, 2H,
J¼ 8.6 Hz, Ar-H), 5.41 (s, 2H, -OCH2-), 2.35 (s, 3H, CH3SO3–). 13C
NMR (75MHz, DMSO-d6) d¼ 171.2 (s), 165.3 (s), 161.1 (s), 156.7 (s),
143.3 (s), 136.5 (s), 134.5 (s), 129.9 (d, 2C), 129.4 (d, 2C), 128.8 (d),
126.3 (d), 125.3 (s), 124.6 (s), 123.2 (d), 123.1 (d), 122.5 (d), 120.2
(d, 2C), 115.7 (d, 2C), 61.34 (t). LC-MS (ESI) m/z: 427.3 (MþHþ)
calcd. for free base M¼ 426.13. Analysis calcd. for C24H22N6O4S2




According to the above-mentioned general method, 4-f[1-(4-
chlorophenyl)-1H-1,2,3-triazol-4-yl]methoxygbenzaldehyde 3b
(79mg, 0.25mmol) and 2-amino-5-amidiniumbenzenethiolate 7
(42mg, 0.25mmol) were used and refluxed for 3 h, giving 103mg
(0.223mmol) of crude free base. Afterwards, the obtained free
base was suspended in ethanol (5ml) followed by the addition of
methanesulfonic acid (16 ml, 0.25mmol) and stirring at room tem-
perature for 2 h. The reaction mixture was cooled overnight, the
resulting precipitate was filtered off, crystallised from ethanol and
dried at 75 C. Yield of pure compound 10b as colourless solid
was 51mg (39.2%), mp ¼ 276–279 C. 1H NMR (300MHz, DMSO-
d6) d¼ 9.23 (s, 4H, -C(NH2)2þ), 9.04 (s, 1H, Ar-H), 8.63 (s, 1H, Ar-H),
8.22 (d, 1H, J¼ 8.8 Hz, Ar-H), 8.14 (d, 2H, J¼ 8.9 Hz, Ar-H), 7.98 (d,
2H, J¼ 8.8 Hz, Ar-H), 7.90 (d, 1H, J¼ 8.9 Hz, Ar-H), 7.70 (d, 2H,
J¼ 8.5 Hz, Ar-H), 7.31 (d, 2H, J¼ 8.8 Hz, Ar-H), 5.40 (s, 2H, -OCH2-),
2.33 (s, 3H, CH3SO3
–). 13C NMR (151MHz, DMSO-d6) d¼ 171.2 (s),
165.3 (s), 161.1 (s), 156.7 (s), 143.5 (s), 135.3 (s), 134.5 (s), 133.1 (s),
129.9 (d, 2C), 129.4 (d, 2C), 129.1 (d), 126.3 (d), 125.3 (s), 124.6 (s),
123.1 (d), 122.5 (d), 121.9 (d, 2C), 115.7 (d, 2C), 61.3 (t), 39.7 (q).
LC-MS (ESI) m/z: 461.2 (MþHþ) calcd. for free base M¼ 460.09.
Analysis calcd. for C24H21ClN6O4S2 (557.04): C, 51.75; H, 3.80; N,
15.09%; Found C, 51.60; H, 3.98; N, 15.12%.
6-Amidinium-2-f[1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-
yl]methoxyg benzothiazole methanesulfonate (10c)
According to the above-mentioned general method, 4-f[1-(4-
methoxyphenyl)-1H-1,2,3-triazol-4-yl]methoxygbenzaldehyde 3c
(77mg, 0.25mmol) and 2-amino-5-amidiniumbenzenethiolate 7
(42mg, 0.25mmol) were used and refluxed for 3 h, giving 97mg
(0.212mmol) of crude free base. Afterwards, the obtained free
base was suspended in ethanol (5ml) followed by the addition of
methanesulfonic acid (16 ml, 0.25mmol) and stirring at room tem-
perature for 2 h. The reaction mixture was cooled overnight, the
resulting precipitate was filtered off, crystallised from ethanol and
dried at 75 C. Yield of pure compound 10c as colourless solid
was 65mg (45.5%), mp ¼ 265–270 C. 1H NMR (300MHz, DMSO-
d6) d¼ 9.15 (s, 4H, -C(NH2)2þ), 8.83 (s, 1H, Ar-H), 8.63 (s, 1H, Ar-H),
8.21 (d, 1H, J¼ 8.6 Hz, Ar-H), 8.13 (d, 2H, J¼ 8.8 Hz, Ar-H), 7.92 (d,
1H, J¼ 8.5 Hz, Ar-H), 7.81 (d, 2H, J¼ 8.9 Hz, Ar-H), 7.32 (d, 2H,
J¼ 8.8 Hz, Ar-H), 7.15 (d, 2H, J¼ 8.9 Hz, Ar-H), 5.38 (s, 2H, -OCH2-),
3.85 (s, 3H, -OCH3), 2.34 (s, 3H, CH3SO3
–). 13C NMR (151MHz,
DMSO-d6) d¼ 171.2 (s), 165.3 (s), 161.1 (s), 159.3 (s), 156.7 (s),
143.1 (s), 134.5 (s), 129.9 (s), 129.4 (d, 2C), 126.3 (d), 125.3 (s),
124.6 (s), 123.1 (d), 123.0 (d), 122.5 (d), 121.8 (d, 2C), 115.7 (d, 2C),
114.9 (d, 2C), 61.4 (t), 55.6 (q), 39.7 (q). LC-MS (ESI) m/z: 457.2
(MþHþ) calcd. for free base M¼ 456.14. Analysis calcd. for
C25H24N6O5S2  H2O (570.64): C, 52.62; H, 4.59; N, 14.73%; Found
C, 52.71; H, 4.62; N, 14.68%.
6-Amidinium-2-[(1-benzyl-1H-1,2,3-triazol-4-yl)methoxy]benzothia-
zole methanesulfonate (10d)
According to the above-mentioned general method, 4-[(1-benzyl-
1H-1,2,3-triazol-4-yl)methoxy]benzaldehyde 3d (148mg, 0. 5mmol)
and 2-amino-5-amidiniumbenzenethiolate 7 (84mg, 0.5mmol)
were used and refluxed for 2 h, giving 149mg (0.277mmol) of
crude free base. Afterwards, the obtained free base was sus-
pended in 2-propanole (10ml) followed by the addition of metha-
nesulfonic acid (20ml, 0.31mmol) and stirring at room
temperature for 2 h. The reaction mixture was cooled overnight,
the resulting precipitate was filtered off, crystallised from ethanol
and dried at 75 C. Yield of pure compound 10d as pale yellow
solid was 76mg (28.4%), mp ¼ 253–257 C. 1H NMR (300MHz,
DMSO-d6) d¼ 9.40 (s, 2H, -C(NH2)2þ), 9.02 (s, 2H, -C(NH2)2þ), 8.62
(d, 1H, J¼ 1.3 Hz, Ar-H), 8.34 (s, 1H, Ar-H), 8.22 (d, 1H, J¼ 8.6 Hz,
Ar-H), 8.11 (d, 2H, J¼ 8.7 Hz, Ar-H), 7.89 (dd, 1H, J¼ 1.6 Hz,
J¼ 8.7 Hz, Ar-H), 7.46–7.30 (m, 5H, Ar-H), 7.26 (d, 2H, J¼ 8.8 Hz, Ar-
H), 5.63 (s, 2H, -CH2-), 5.28 (s, 2H, -OCH2-), 2.32 (s, 3H, CH3SO3
–).
13C NMR (75MHz, DMSO-d6) d¼ 171.2 (s), 165.3 (s), 161.2 (s),
156.7 (s), 142.5 (s), 136.0 (s), 134.5 (s), 129.4 (d, 2C), 128.8 (d, 2C),
128.2 (d), 128.0 (d, 2C), 126.3 (d), 125.2 (s), 124.9 (d), 124.6 (s),
123.2 (d), 122.5 (d), 115.7 (d, 2C), 61.4 (t), 52.9 (t). LC-MS (ESI) m/z:
441.2 (MþHþ) calcd. for free base M¼ 440.14. Analysis calcd. for
C25H24N6O4S2 (536.63): C, 55.95; H, 4.51; N, 15.66%; Found C,
56.08; H, 4.36; N, 15.57%.
6-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2-[(1-phenyl-1H-1,2,3-tria-
zol-4-yl)methoxy] benzothiazole methanesulfonate (11a)
According to the above-mentioned general method, 4-[(1-phenyl-
1H-1,2,3-triazol-4-yl)methoxy]benzaldehyde 3a (70mg, 0.25mmol)
and 2-amino-5-(4,5-dihydro-1H-imidazol-3-ium-2-yl)benzenethiolate
hydrate 8 (53mg, 0.25mmol) were used and refluxed for 2 h, giv-
ing 88mg (0.195mmol) of crude free base. Afterwards, the
obtained free base was suspended in ethanol (5ml) followed by
the addition of methanesulfonic acid (15 ml, 0.23mmol) and stir-
ring at room temperature for 2 h. The reaction mixture was cooled
overnight, the resulting precipitate was filtered off and dried at
75 C. Yield of pure compound 11a as colourless solid was 74mg
(54%), mp ¼ 270–274 C. 1H NMR (600MHz, DMSO-d6) d¼ 10.56
(s, 2H, -C(NH-)2
þ), 9.01 (s, 1H, Ar-H), 8.73 (s, 1H, Ar-H), 8.33–7.85
(m, 6H, Ar-H), 7.69–7.25 (m, 5H, Ar-H), 5.40 (s, 2H, -OCH2-), 4.06 (s,
4H, -CH2CH2-), 2.33 (s, 3H, CH3SO3
–). 13C NMR (75MHz, DMSO-d6)
d¼ 171.8 (s), 164.8 (s), 161.2 (s), 157.1 (s), 143.3 (s), 136.5 (s), 134.8
(s), 129.9 (d, 2C), 129.5 (d, 2C), 128.8 (d), 126.4 (d), 125.2 (s), 123.4
(d), 123.1 (d), 122.9 (d), 120.2 (d, 2C), 118.4 (s), 115.7 (d, 2C), 61.3
(t). LC-MS (ESI) m/z: 455.3 (MþHþ) calcd. for free base M¼ 452.14.
Analysis calcd. for C26H24N6O4S2 (548.64): C, 56.92; H, 4.41; N,
15.32%; Found C, 56.78; H, 4.37; N, 15.37%.
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6-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2-f[1-(4-chlorophenyl)-1H-
1,2,3-triazol-4-yl]methoxygbenzothiazole methanesulfonate (11b)
According to the above-mentioned general method, 4-f[1-(4-
chlorophenyl)-1H-1,2,3-triazol-4-yl]methoxygbenzaldehyde 3b
(79mg, 0.25mmol) and 2-amino-5-(4,5-dihydro-1H-imidazol-3-ium-
2-yl)benzenethiolate hydrate 8 (53mg, 0.25mmol) were used and
refluxed for 2 h, giving 110mg (0.225mmol) of crude free base.
Afterwards, the obtained free base was suspended in ethanol
(10ml) followed by the addition of methanesulfonic acid (16 ml,
0.25mmol) and stirring at room temperature for 2 h. The reaction
mixture was cooled overnight, the resulting precipitate was fil-
tered off and dried at 75 C. Yield of pure compound 11b as col-
ourless solid was 93mg (64.1%), mp ¼ 263–266 C. 1H NMR
(600MHz, DMSO-d6) d¼ 10.56 (s, 2H, -C(NH-)2þ), 9.04 (s, 1H, Ar-H),
8.72 (s, 1H, Ar-H), 8.26 (d, J¼ 8.2 Hz, 1H, Ar-H), 8.14 (m, 2H, Ar-H),
8.05–7.93 (m, 3H, Ar-H), 7.70 (m, 2H, Ar-H), 7.32 (m, 2H, Ar-H), 5.40
(s, 2H, -OCH2-), 4.06 (s, 4H, -CH2CH2-), 2.32 (s, 3H, CH3SO3
–). 13C
NMR (151MHz, DMSO-d6) d¼ 171.8 (s), 164.9 (s), 161.2 (s), 157.1
(s), 143.5 (s), 135.3 (s), 134.8 (s), 133.1 (s), 129.9 (d, 2C), 129.5 (d,
2C), 126.4 (d), 125.2 (s), 123.4 (d), 123.2 (d), 123.0 (d), 121.9 (d, 2C),
118.4 (s), 115.7 (d, 2C), 61.31 (t), 44.5 (t, 2C), 39.7 (q). LC-MS (ESI)
m/z: 487.2 (MþHþ) calcd. for free base M¼ 486.10. Analysis calcd.
for C26H23ClN6O4S2 (583.08): C, 53.56; H, 3.98; N, 14.41%; Found C,
53.43; H, 3.93; N, 14.34%.
6-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2-f[1-(4-methoxyphenyl)-1H-
1,2,3-triazol-4-yl]methoxygbenzothiazole methanesulfonate (11c)
According to the above-mentioned general method, 4-f[1-(4-
methoxyphenyl)-1H-1,2,3-triazol-4-yl]methoxygbenzaldehyde 3c
(77mg, 0.25mmol) and 2-amino-5-(4,5-dihydro-1H-imidazol-3-ium-
2-yl)benzenethiolate hydrate 8 (53mg, 0.25mmol) were used and
refluxed for 3 h, giving 101mg (0.209mmol) of crude free base.
Afterwards, the obtained free base was suspended in ethanol
(5ml) followed by the addition of methanesulfonic acid (15 ml,
0.23mmol) and stirring at room temperature for 2 h. The reaction
mixture was cooled overnight, the resulting precipitate was fil-
tered off and dried at 75 C. Yield of pure compound 11c as col-
ourless solid was 82mg (45.5%), mp ¼ 253–257 C. 1H NMR
(600MHz, DMSO-d6) d¼ 10.55 (s, 2H, -C(NH-)2þ), 8.89 (s, 1H, Ar-H),
8.72 (s, 1H, Ar-H), 8.26 (d, J¼ 8.2 Hz, 1H, Ar-H), 8.14 (d, 2H,
J¼ 7.3 Hz, Ar-H), 8.01 (d, 1H, J¼ 8.3 Hz, Ar-H), 7.82 (d, 2H,
J¼ 7.2 Hz, Ar-H), 7.32 (d, 2H, J¼ 7.3 Hz, Ar-H), 7.15 (d, 2H,
J¼ 7.4 Hz, Ar-H), 5.38 (s, 2H, -OCH2-), 4.06 (s, 4H, -CH2CH2-), 3.84 (s,
3H, -OCH3), 2.31 (s, 3H, CH3SO3
–). 13C NMR (75MHz, DMSO-d6)
d¼ 171.8 (s), 164.8 (s), 161.3 (s), 159.3 (s), 157.1 (s), 143.1 (s), 134.8
(s), 129.9 (s), 129.5 (d, 2C), 126.4 (d), 125.1 (s), 123.4 (d), 123.1 (d),
122.9 (d), 121.8 (d, 2C), 118.4 (s), 115.7 (d, 2C), 114.9 (d, 2C), 61.4
(t), 55.6 (q), 44.6 (t, 2C). LC-MS (ESI) m/z: 483.3 (MþHþ) calcd. for
free base M¼ 482.15. Analysis calcd. for C27H26N6O5S2 (578.66): C,
56.04; H, 4.53; N, 14.52%; Found C, 56.18; H, 4.57; N, 14.51%.
6-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2[(1-benzyl-1H-1,2,3-triazol-
4-yl)methoxy]benzothiazole methanesulfonate (11d)
According to the above-mentioned general method, 4-[(1-benzyl-
1H-1,2,3-triazol-4-yl)methoxy]benzaldehyde 3d (74mg, 0.25mmol)
and 2-amino-5-(4,5-dihydro-1H-imidazol-3-ium-2-yl)benzenethiolate
hydrate 8 (53mg, 0.25mmol) were used and refluxed for 2 h, giv-
ing 88mg (0.182mmol) of crude free base. Afterwards, the
obtained free base was suspended in 2-propanol (5ml) followed
by the addition of methanesulfonic acid (13ml, 0.20mmol) and
stirring at room temperature for 2 h. The reaction mixture was
cooled overnight, the resulting precipitate was filtered off and
dried at 75 C. Yield of pure compound 11d as colourless solid
was 65mg (46.1%), mp ¼ 227–232 C. 1H NMR (600MHz, DMSO-
d6) d¼ 10.55 (s, 2H, -C(NH-)2þ), 8.71 (s, 1H, Ar-H), 8.34 (s, 1H, Ar-
H), 8.26 (d, 1H, J¼ 8.3 Hz, Ar-H), 8.12 (d, 2H, J¼ 7.4 Hz, Ar-H), 8.01
(d, 1H, J¼ 8.4 Hz, Ar-H), 7.46–7.30 (m, 5H, Ar-H), 7.27 (d, 2H,
J¼ 7.5 Hz, Ar-H), 5.63 (s, 2H,-CH2-), 5.28 (s, 2H, -OCH2-), 4.06 (s, 4H,
-CH2CH2-), 2.31 (s, 3H, CH3SO3
–). 13C NMR (75MHz, DMSO-d6)
d¼ 171.6 (s), 164.7 (s), 161.2 (s), 157.0 (s), 142.3 (s), 135.7 (s), 134.7
(s), 129.2 (d, 2C), 128.5 (d), 128.0 (d), 127.7 (d), 126.2 (d), 125.0 (s),
124.6 (d), 123.2 (d), 122.7 (d), 118.2 (s), 115.6 (d,2C), 61.4 (t), 52.7
(t), 44.4 (t, 2C), 39.6 (q). LC-MS (ESI) m/z: 467.3 (MþHþ) calcd. for
free base M¼ 466.16. Analysis calcd. for C27H26N6O4S2 (562.66): C,
57.63; H, 4.66; N, 14.94%; Found C, 57.47; H, 4.76; N, 15.01%.
6-(3,4,5,6-Tetrahydropyrimidin-1-ium-2-yl)-2-[(1-phenyl-1H-1,2,3-tri-
azol-4-yl)methoxy] benzothiazole methanesulfonate (12a)
According to the above-mentioned general method, 4-[(1-phenyl-
1H-1,2,3-triazol-4-yl)methoxy]benzaldehyde 3a (70mg, 0.25mmol)
and 2-amino-5-(3,4,5,6-tetrahydropyrimidin-1-ium-2-yl)benzene-
thiolate 9 (52mg, 0.25mmol) were used and refluxed for 4 h, giv-
ing 75mg (0.160mmol) of crude free base. Afterwards, the
obtained free base was suspended in 2-propanol (5ml) followed
by the addition of methanesulfonic acid (12 ml, 0.18mmol) and
stirring at room temperature for 2 h. The reaction mixture was
cooled overnight, the resulting precipitate was filtered off and
dried at 75 C. Yield of pure compound 12a as colourless solid
was 64mg (44.1%), mp ¼ 249–254 C. 1H NMR (300MHz, DMSO-
d6) d¼ 9.95 (s, 2H, -C(NH-)2þ), 8.95 (s, 1H, Ar-H), 8.52 (s, 1H, Ar-H),
8.22 (d, 1H, J¼ 8.7 Hz, Ar-H), 8.13 (d, 2H, J¼ 8.3 Hz, Ar-H), 7.92 (d,
2H, J¼ 7.7 Hz, Ar-H), 7.82 (d, 1H, J¼ 8.5 Hz, Ar-H), 7.69–7.48 (m, 3H,
Ar-H), 7.32 (d, 2H, J¼ 8.5 Hz, Ar-H), 5.40 (s, 2H, -OCH2-), 3.55 (m,
4H, -CH2CH2CH2-), 2.30 (s, 3H, CH3SO3
–), 2.04 (m, 2H, -CH2CH2CH2-
). 13C NMR (151MHz, DMSO-d6) d¼ 170.7 (s), 161.0 (s), 159.0 (s),
156.2 (s), 143.2 (s), 136.4 (s), 134.4 (s), 129.7 (d, 2C), 129.2 (d, 2C),
128.6 (d), 125.6 (d), 125.2 (s), 124.8 (s), 122.8 (d), 122.5 (d), 122.2
(d), 120.0 (d, 2C), 115.6 (d, 2C), 61.3 (t), 39.64 (q), 38.8 (t, 2C), 17.6
(t). LC-MS (ESI) m/z: 467.3 (MþHþ) calcd. for free base M¼ 466.16.
Analysis calcd. for C27H26N6O4S2  H2O (580.68): C, 55.85; H, 4.86;
N, 14.47%; Found C, 56.09; H, 4.69; N, 14.58%.
6-(3,4,5,6-Tetrahydropyrimidin-1-ium-2-yl)-2-[(1-(4-Chlorophenyl)-1H-
1,2,3-triazol-4-yl]methoxy)benzothiazole methanesulfonate (12b)
According to the above-mentioned general method, 4-f[1-(4-
chlorophenyl)-1H-1,2,3-triazol-4-yl]methoxygbenzaldehyde 3b
(79mg, 0.25mmol) and 2-amino-5-(3,4,5,6-tetrahydropyrimidin-1-
ium-2-yl)benzenethiolate 9 (52mg, 0.25mmol) were used and
refluxed for 3 h, giving 109mg (0.218mmol) of crude free base.
Afterwards, the obtained free base was suspended in 2-propanol
(10ml) followed by the addition of methanesulfonic acid (15ml,
0.23mmol) and stirring at room temperature for 2 h. The reaction
mixture was cooled overnight, the resulting precipitate was fil-
tered off and dried at 75 C. Yield of pure compound 12b as col-
ourless solid was 67mg (45.0%), mp ¼ 220–224 C. 1H NMR
(300MHz, DMSO-d6) d¼ 9.93 (s, 2H, -C(NH-)2þ), 8.95 (s, 1H, Ar-H),
8.51 (s, 1H, Ar-H), 8.21 (d, 1H, J¼ 8.4 Hz, Ar-H), 8.13 (d, 2H,
J¼ 8.6 Hz, Ar-H), 7.96 (d, 2H, J¼ 8.7 Hz, Ar-H), 7.82 (d, 1H,
J¼ 7.2 Hz, Ar-H), 7.68 (d, 2H, J¼ 8.6 Hz, Ar-H), 7.31 (d, 2H,
J¼ 8.6 Hz, Ar-H), 5.41 (s, 2H, -OCH2-), 3.55 (t, J¼ 5.3 Hz, 4H,
-CH2CH2CH2-), 2.31 (s, 3H, CH3SO3
–), 2.04 (m, 2H, -CH2CH2CH2-).
13C NMR (151MHz, DMSO-d6) d¼ 170.7 (s), 160.9 (s), 159.0 (s),
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156.2 (s), 143.4 (s), 135.2 (s), 134.4 (s), 132.9 (s), 129.6 (d, 2C), 129.2
(d, 2C), 125.6 (d), 125.3 (s), 124.8 (s), 122.9 (d), 122.5 (d), 122.2 (d),
121.7 (d, 2C), 115.6 (d, 2C), 61.3 (t), 39.6 (q), 38.8 (t, 2C), 17.6 (t).
LC-MS (ESI) m/z: 501.3 (MþHþ) calcd. for free base M¼ 500.12.
Analysis calcd. for C27H25ClN6O4S2 (583.08): C, 54.31; H, 4.22; N,
14.07%; Found C, 54.61; H, 3.99; N, 14.04%.
6-(3,4,5,6-Tetrahydropyrimidin-1-ium-2-yl)-2-f[1-(4-methoxyphenyl)-
1H-1,2,3-triazol-4-yl]methoxygbenzothiazole methanesulfonate (12c)
According to the above-mentioned general method, 4-f[1-(4-
methoxyphenyl)-1H-1,2,3-triazol-4-yl]methoxygbenzaldehyde 3c
(77mg, 0.25mmol) and 2-amino-5-(3,4,5,6-tetrahydropyrimidin-1-
ium-2-yl)benzenethiolate 9 (52mg, 0.25mmol) were used and
refluxed for 2 h, giving 101mg (0.203mmol) of crude free base.
Afterwards, the obtained free base was suspended in ethanol
(5ml) followed by the addition of methanesulfonic acid (15 ml,
0.23mmol) and stirring at room temperature for 2 h. The reaction
mixture was cooled overnight, diethyl-ether was added and the
resulting precipitate was filtered off, and dried at 75 C. Yield of
pure compound 12c as colourless solid was 60mg (39.2%), mp ¼
259–264 C. 1H NMR (300MHz, DMSO-d6) d¼ 9.96 (s, 2H, -C(NH-
)2
þ), 8.84 (s, 1H, Ar-H), 8.52 (d, 1H, J¼ 1.5 Hz, Ar-H), 8.21 (d, 1H,
J¼ 8.6 Hz, Ar-H), 8.13 (d, 2H, J¼ 8.8 Hz, Ar-H), 7.84–7.80 (m, 3H),
7.31 (d, 2H, J¼ 8.8 Hz, Ar-H), 7.15 (d, 2H, J¼ 9.0 Hz, Ar-H), 5.38 (s,
2H, -OCH2-), 3.85 (s, 3H, -OCH3), 3.55 (t, 4H, J¼ 5.6 Hz,
-CH2CH2CH2-), 2.31 (s, 3H, CH3SO3
–), 2.04 (m, 2H, -CH2CH2CH2-).
13C NMR (151MHz, DMSO-d6) d¼ 170.8 (s), 161.0 (s), 159.3 (s),
159.1 (s), 156.2 (s), 143.0 (s), 134.5 (s), 129.8 (s), 129.2 (d, 2C), 125.6
(d), 125.2 (s), 124.9 (s), 122.8 (d), 122.5 (d), 122.3 (d), 121.7 (d, 2C),
115.6 (d, 2C), 114.8 (d, 2C), 61.3 (t), 55.4 (q), 39.6 (q), 38.8 (t, 2C),
17.6 (t). LC-MS (ESI) m/z: 497.3 (MþHþ) calcd. for free base
M¼ 496.17. Analysis calcd. for C28H28N6O5S2  H2O (610.70): C,
55.07; H, 4.95; N, 13.76%; Found C, 54.91; H, 4.99; N, 13.87%.
6-(3,4,5,6-Tetrahydropyrimidin-1-ium-2-yl)-2-[(1-benzyl-1H-1,2,3-tri-
azol-4-yl)methoxy]benzothiazole methanesulfonate (12d)
According to the above-mentioned general method, 4-[(1-benzyl-
1H-1,2,3-triazol-4-yl)methoxy]benzaldehyde 3d (148mg, 0.5mmol)
and 2-amino-5-(3,4,5,6-tetrahydropyrimidin-1-ium-2-yl)benzene-
thiolate 9 (104mg, 0.5mmol) were used and refluxed for 2 h, giv-
ing 188mg (0.391mmol) of crude free base. Afterwards, the
obtained free base was suspended in 2-propanol (5ml) followed
by the addition of methanesulfonic acid (28ml, 0.43mmol) and
stirring at room temperature for 2 h. To the reaction mixture
diethyl-ether was added, the resulting precipitates was filtered off,
crystalised from 2-propanole and dried at 75 C. Yield of pure
compound 12d as colourless solid was 47mg (15.8%), mp ¼
197–199 C. 1H NMR (300MHz, DMSO-d6) d¼ 10.01 (s, 2H, -C(NH-
)2
þ), 8.52 (d, 1H, J¼ 1.3 Hz, Ar-H), 8.34 (s, 1H, Ar-H), 8.22 (d, 1H,
J¼ 8.5 Hz, Ar-H), 8.11 (d, 2H, J¼ 8.7 Hz, Ar-H), 7.80 (dd, 1H,
J¼ 1.5 Hz, J¼ 8.6 Hz, Ar-H), 7.42–7.32 (m, 5H, Ar-H), 7.26 (d, 2H,
J¼ 8.8 Hz, Ar-H), 5.63 (s, 2H, -CH2-), 5.28 (s, 2H, -OCH2-), 3.53 (t,
J¼ 5.4 Hz, 4H, -CH2CH2CH2-), 2.29 (s, 3H, CH3SO3–), 2.01 (m, 2H,
-CH2CH2CH2-).
13C NMR (75MHz, DMSO-d6) d¼ 170.9 (s), 161.2 (s),
159.1 (s), 156.3 (s), 142.5 (s), 136.0 (s), 134.6 (s), 129.3 (d, 2C), 128.8
(d, 2C), 128.2 (d), 128.0 (d, 2C), 125.9 (d), 125.2 (s), 125.0 (s), 124.9
(d), 122.7 (d), 122.5 (d), 115.7 (d, 2C), 61.4 (t), 52.8 (t), 39.7 (q), 38.9
(t, 2C), 17.7 (t). LC-MS (ESI) m/z: 481.3 (MþHþ) calcd. for free base
M¼ 480.17. Analysis calcd. for C28H28N6O4S2  H2O (594.70): C,
56.55; H, 5.08; N, 14.13%; Found C, 56.78; H, 5.26; N, 14.02%.
6-Amidinium-2-(1-phenyl-1H-1,2,3-triazole-4-yl)benzothiazole
methanesulfonate (13a)
According to the above-mentioned general method, 1-phenyl-1H-
1,2,3-triazole-4-carbaldehyde 6a (87mg, 0.5mmol) and 2-amino-5-
amidiniumbenzenethiolate 7 (84mg, 0.5mmol) were used and
refluxed for 2 h, giving 126mg (0.394mmol) of crude free base.
Afterwards, the obtained free base was suspended in ethanol
(10ml) followed by the addition of methanesulfonic acid (29ml,
0.45mmol) and stirring at room temperature for 2 h. The reaction
mixture was cooled overnight, the resulting precipitate was fil-
tered off and dried at 75 C. Yield of pure compound 13a as col-
ourless solid was 123mg (76.8%), mp ¼ 289–293 C. 1H NMR
(300MHz, DMSO-d6) d¼ 9.76 (s, 1H, Ar-H), 9.45 (s, 2H, -C(NH2)2þ),
9.11 (s, 2H, -C(NH2)2
þ), 8.72 (s, 1H, Ar-H), 8.28 (d, 1H, J¼ 8.6 Hz, Ar-
H), 8.06 (d, 2H, J¼ 7.6 Hz, Ar-H), 7.95 (d, 1H, J¼ 8.4 Hz, Ar-H),
7.70–7.56 (m, 3H, Ar-H), 2.35 (s, 3H, CH3SO3
–). 13C NMR (75MHz,
DMSO-d6) d¼ 165.4 (s), 162.7 (s), 156.3 (s), 142.4 (s), 136.1 (s),
134.2 (s), 130.0 (d, 2C), 129.5 (d), 126.5 (d), 125.3 (s), 123.6 (d),
122.8 (d), 122.7 (d), 120.6 (d, 2C), 39.8 (q). LC-MS (ESI) m/z: 321.2
(MþHþ) calcd. for free base M¼ 320.08. Analysis calcd. for
C17H16N6O3S2 (416.48): C, 49.23; H, 3.87; N, 20.18%; Found C,
49.28; H, 4.02; N, 20.01%.
6-Amidinium-2-[1-(4-chlorophenyl)-1H-1,2,3-triazole-4-yl]benzo-
thiazole methanesulfonate (13b)
According to the above-mentioned general method, 1-(4-chloro-
phenyl)-1H-1,2,3-triazole-4-carbaldehyde 6b (104mg, 0.5mmol)
and 2-amino-5-amidiniumbenzenethiolate 7 (84mg, 0.5mmol)
were used and refluxed for 3 h, giving 151mg (0.394mmol) of
crude free base. Afterwards, the obtained free base was sus-
pended in ethanol (10ml) followed by the addition of methane-
sulfonic acid (29ml, 0.45mmol) and stirring at room temperature
for 2 h. The reaction mixture was cooled overnight, the resulting
precipitate was filtered off and dried at 75 C. Yield of pure com-
pound 13b as colourless solid was 143mg (63.6%), mp > 300 C.
1H NMR (300MHz, DMSO-d6) d¼ 9.70 (s, 1H, Ar-H), 9.18 (s, 4H,
-C(NH2)2
þ), 8.70 (s, 1H, Ar-H), 8.25 (d, 1H, J¼ 8.3 Hz, Ar-H), 8.08 (d,
2H, J¼ 8.0 Hz, Ar-H), 7.95 (d, 1H, J¼ 7.8 Hz, Ar-H), 7.73 (d, 2H,
J¼ 7.6 Hz, Ar-H), 2.34 (s, 3H, CH3SO3–). 13C NMR (75MHz, DMSO-
d6) d¼ 165.1 (s), 162.2 (s), 155.9 (s), 142.2 (s), 134.7 (s), 134.0 (s),
133.6 (s), 129.5 (d, 2C), 126.0 (d), 125.2 (s), 123.0 (d), 122.5 (d),
122.1 (d, 2C), 39.4 (q). LC-MS (ESI) m/z: 355.1 (MþHþ) calcd. for
free base M¼ 354.05. Analysis calcd. for C17H15ClN6O3S2 (450.92):
C, 45.28; H, 3.35; N, 18.64%; Found C, 45.28; H, 3.21; N, 18.71%.
6-Amidinium-2-[1-(4-methoxyphenyl)-1H-1,2,3-triazole-4-yl]benzo-
thiazole methanesulfonate (13c)
According to the above-mentioned general method, 1-(4-methoxy-
phenyl)-1H-1,2,3-triazole-4-carbaldehyde 6c (102mg, 0.5mmol)
and 2-amino-5-amidiniumbenzenethiolate 7 (84mg, 0.5mmol)
were used and refluxed for 2 h, giving 130mg (0.371mmol) of
crude free base. Afterwards, the obtained free base was sus-
pended in ethanol (10ml) followed by the addition of methane-
sulfonic acid (26ml, 0.40mmol) and stirring at room temperature
for 2 h. The reaction mixture was cooled overnight, the resulting
precipitate was filtered off and dried at 75 C. Yield of pure com-
pound 13c as colourless solid was 114mg (50.0%), mp > 300 C.
1H NMR (300MHz, DMSO-d6) d¼ 9.65 (s, 1H, Ar-H), 9.45 (s, 2H,
-C(NH2)2
þ), 9.11 (s, 2H, -C(NH2)2
þ), 8.71 (s, 1H, Ar-H), 8.27 (d, 1H,
J¼ 8.1 Hz, Ar-H), 8.08–7.87 (m, 3H, Ar-H), 7.20 (d, 2H, J¼ 7.1 Hz, Ar-
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H), 3.86 (s, 3H, -OCH3), 2.35 (s, 3H, CH3SO3
–). 13C NMR (151MHz,
DMSO-d6) d¼ 165.3 (s), 162.8 (s), 159.8 (s), 156.2 (s), 142.1 (s),
134.1 (s), 129.4 (s), 126.3 (d), 125.1 (s), 123.4 (d), 122.7 (d), 122.5
(d), 122.2 (d, 2C), 114.9 (d, 2C), 55.6 (q), 39.7 (q). LC-MS (ESI) m/z:
351.1 (MþHþ) calcd. for free base M¼ 350.09. Analysis calcd. for
C18H18N6O4S2  0.5 H2O (455.51): C, 47.46; H, 4.20; N, 18.45%;
Found C, 47.62; H, 4.12; N, 18.35%.
6-Amidinium-2-(1-benzyl-1H-1,2,3-triazole-4-yl)benzothiazole
methanesulfonate (13d)
According to the above-mentioned general method, 1-benzyl-1H-
1,2,3-triazole-4-carbaldehyde 6d (94mg, 0.5mmol) and 2-amino-5-
amidiniumbenzenethiolate 7 (84mg, 0.5mmol) were used and
refluxed for 3 h, giving 78mg (0.233mmol) of crude free base.
Afterwards, the obtained free base was suspended in ethanol
(5ml) followed by the addition of methanesulfonic acid (16 ml,
0.25mmol) and stirring at room temperature for 2 h. The reaction
mixture was cooled overnight, the resulting precipitate was fil-
tered off and dried at 75 C. Yield of pure compound 13d as col-
ourless solid was 80mg (35.7%), mp ¼ 262–267 C. 1H NMR
(300MHz, DMSO-d6) d¼ 9.33 (s, 2H, -C(NH2)2þ), 9.02 (s, 1H, Ar-H),
8.96 (s, 2H, -C(NH2)2
þ), 8.66 (s, 1H, Ar-H), 8.21 (d, 1H, J¼ 8.5 Hz, Ar-
H), 7.94 (d, 1H, J¼ 8.6 Hz, Ar-H), 7.43–7.35 (m, 5H, Ar-H), 5.75 (s,
2H, -CH2-), 2.36 (s, 3H, CH3SO3
–). 13C NMR (151MHz, DMSO-d6)
d¼ 165.3 (s), 163.0 (s), 156.2 (s), 141.6 (s), 135.3 (s), 134.0 (s), 128.7
(d, 2C), 128.3 (d), 128.0 (d, 2C), 126.2 (d), 125.0 (s), 124.6 (d), 123.3
(d), 122.6 (d), 53.4 (t), 39.7 (q). LC-MS (ESI) m/z: 335.2 (MþHþ)
calcd. for free base M¼ 334.10. Analysis calcd. for C18H18N6O3S2 




According to the above-mentioned general method, 1-phenyl-1H-
1,2,3-triazole-4-carbaldehyde 6a (87mg, 0.5mmol) and 2-amino-5-
(4,5-dihydro-1H-imidazol-3-ium-2-yl)benzenethiolate hydrate 8
(106mg, 0.5mmol) were used and refluxed for 3 h, giving 137mg
(0.396mmol) of crude free base. Afterwards, the obtained free
base was suspended in ethanol (10ml) followed by the addition
of methanesulfonic acid (29 ml, 0.44mmol) and stirring at room
temperature for 2 h. The reaction mixture was cooled overnight,
the resulting precipitate was filtered off and dried at 75 C. Yield
of pure compound 14a as colourless solid was 147mg (66.5%),
mp ¼ 283–287 C. 1H NMR (300MHz, DMSO-d6) d¼ 10.56 (s, 2H,
C(NH-)2
þ), 9.70 (s, 1H, Ar-H), 8.81 (s, 1H, Ar-H), 8.31 (d, 1H,
J¼ 8.6 Hz, Ar-H), 8.13–8.04 (m, 3H, Ar-H), 7.69–7.56 (m, 3H, Ar-H),
4.08 (s, 4H, -CH2CH2-), 2.33 (s, 3H, CH3SO3
–). 13C NMR (151MHz,
DMSO-d6) d¼ 164.7 (s), 162.9 (s), 156.4 (s), 141.9 (s), 135.8 (s),
134.3 (s), 129.5 (d, 2C), 129.0 (d), 126.1 (d), 123.4 (d), 122.8 (d),
122.4 (d), 120.3 (d, 2C), 118.8 (s), 44.3 (t, 2C). LC-MS (ESI) m/z:
347.2 (MþHþ) calcd. for free base M¼ 346.10. Analysis calcd. for
C19H18N6O3S2 (442.51): C, 51.57; H, 4.10; N, 18.99%; Found C,
51.67; H, 4.09; N, 18.87%.
6-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2-[1-(4-chlorophenyl)-1H-
1,2,3-triazole-4-yl]benzothiazole methanesulfonate (14b)
According to the above-mentioned general method, 1-(4-chloro-
phenyl)-1H-1,2,3-triazole-4-carbaldehyde 6b (104mg, 0.5mmol)
and 2-amino-5-(4,5-dihydro-1H-imidazol-3-ium-2-yl)benzenethiolate
hydrate 8 (106mg, 0.5mmol) were used and refluxed for 3 h,
giving 138mg (0.362mmol) of crude free base. Afterwards, the
obtained free base was suspended in ethanol (10ml) followed by
the addition of methanesulfonic acid (26 ml, 0.40mmol) and stir-
ring at room temperature for 2 h. The reaction mixture was cooled
overnight, the resulting precipitate was filtered off and dried at
75 C. Yield of pure compound 14b as colourless solid was
144mg (60.5%), mp > 300 C. 1H NMR (300MHz, DMSO-d6)
d¼ 10.55 (s, 2H, C(NH-)2þ), 9.73 (s, 1H, Ar-H), 8.80 (s, 1H, Ar-H),
8.31 (d, 1H, J¼ 8.5 Hz, Ar-H), 8.11–8.05 (m, 3H, Ar-H), 7.74 (d, 2H,
J¼ 8.5 Hz, Ar-H), 4.08 (s, 4H, -CH2CH2-), 2.32 (s, 3H, CH3SO3–). 13C
NMR (75MHz, DMSO-d6) d¼ 164.7 (s), 162.9 (s), 156.4 (s), 142.1 (s),
134.7 (s), 134.3 (s), 133.6 (s), 129.6 (d, 2C), 126.3 (d), 123.6 (d),
123.0 (d), 122.7 (d), 122.1 (d, 2C), 118.9 (s), 44.4 (t, 2C). LC-MS (ESI)
m/z: 381.2 (MþHþ) calcd. for free base M¼ 380.06. Analysis calcd.
for C19H17ClN6O3S2 (476.96): C, 47.85; H, 3.59; N, 17.62%; Found C,
47.83; H, 3.55; N, 17.75%.
6-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2-[1-(4-methoxyphenyl)-1H-
1,2,3-triazole-4-yl]benzothiazole methanesulfonate (14c)
According to the above-mentioned general method, 1-(4-methoxy-
phenyl)-1H-1,2,3-triazole-4-carbaldehyde 6c (102mg, 0.5mmol)
and 2-amino-5-(4,5-dihydro-1H-imidazol-3-ium-2-yl)benzenethiolate
hydrate 8 (106mg, 0.5mmol) were used and refluxed for 3 h, giv-
ing 132mg (0.351mmol) of crude free base. Afterwards, the
obtained free base was suspended in ethanol (10ml) followed by
the addition of methanesulfonic acid (25 ml, 0.39mmol) and stir-
ring at room temperature for 2 h. The reaction mixture was cooled
overnight, the resulting precipitate was filtered off and dried at
75 C. Yield of pure compound 14c as colourless solid was 110mg
(46.6%), mp > 300 C. 1H NMR (300MHz, DMSO-d6) d¼ 10.61 (s,
2H, C(NH-)2
þ), 9.66 (s, 1H, Ar-H), 8.80 (s, 1H, Ar-H), 8.31 (d, 1H,
J¼ 7.8 Hz, Ar-H), 8.05 (d, 1H, J¼ 7.3 Hz, Ar-H), 7.97 (d, 2H,
J¼ 7.7 Hz, Ar-H), 7.20 (d, 2H, J¼ 7.5 Hz, Ar-H), 4.07 (s, 4H,
-CH2CH2-), 3.86 (s, 3H, OCH3), 2.32 (s, 3H, CH3SO3
–). 13C NMR
(151MHz, DMSO-d6) d¼ 164.7 (s), 163.2 (s), 159.7 (s), 156.5 (s),
141.9 (s), 134.3 (s), 129.7 (s), 126.3 (d), 123.5 (d), 122.9 (d), 122.4
(d), 122.0 (d, 2C), 118.8 (s), 114.8 (d, 2C), 55.5 (q), 44.4 (t, 2C). LC-
MS (ESI) m/z: 377.2 (MþHþ) calcd. for free base M¼ 376.11.
Analysis calcd. for C20H20N6O4S2 (472.54): C, 50.83; H, 4.27; N,
17.78%; Found C, 50.74; H, 4.33; N, 17.62%.
6-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2-(1-benzyl-1H-1,2,3-tri-
azole-4-yl)benzothiazole methanesulfonate (14d)
According to the above-mentioned general method, 1-benzyl-1H-
1,2,3-triazole-4-carbaldehyde 6d (94mg, 0.5mmol) and 2-amino-5-
(4,5-dihydro-1H-imidazol-3-ium-2-yl)benzenethiolate hydrate 8
(106mg, 0.5mmol) were used and refluxed for 3 h, giving 75mg
(0.233mmol) of crude free base. Afterwards, the obtained free
base was suspended in 2-propanol (5ml) followed by the addition
of methanesulfonic acid (16ml, 0.25mmol) and stirring at room
temperature for 2 h. The reaction mixture was cooled overnight,
the resulting precipitate was filtered off and dried at 75 C. Yield
of pure compound 14d as colourless solid was 75mg (32.9%), mp
¼ 236–240 C. 1H NMR (300MHz, DMSO-d6) d¼ 10.52 (s, 2H,
C(NH-)2
þ), 9.09 (s, 1H, Ar-H), 8.76 (s, 1H, Ar-H), 8.27 (d, 1H,
J¼ 8.3 Hz, Ar-H), 8.03 (d, 1H, J¼ 8.8 Hz, Ar-H), 7.47–7.35 (m, 5H, Ar-
H), 5.75 (s, 2H, -CH2-), 4.07 (s, 4H, -CH2CH2-), 2.32 (s, 3H, CH3SO3
–).
13C NMR (151MHz, DMSO-d6) d¼ 164.8 (s), 163.6 (s), 156.6 (s),
141.5 (s), 135.3 (s), 134.3 (s), 128.7 (d, 2C), 128.3 (d), 128.0 (d, 2C),
126.4 (d), 124.8 (d), 123.7 (d), 123.1 (d), 118.9 (s), 53.4 (t), 44.5 (t,
2C), 39.7 (q). LC-MS (ESI) m/z: 361.2 (MþHþ) calcd. for free base
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M¼ 360.12. Analysis calcd. for C20H20N6O3S2 (456.54): C, 52.62; H,
4.42; N, 18.41%; Found C, 52.69; H, 4.36; N, 18.55%.
6-(3,4,5,6-Tetrahydropyrimidin-1-ium-2-yl)-2-(1-phenyl-1H-1,2,3-tri-
azole-4-yl)benzothiazole methanesulfonate (15a)
According to the above-mentioned general method, 1-phenyl-1H-
1,2,3-triazole-4-carbaldehyde 6a (87mg, 0.5mmol) and 2-amino-5-
(3,4,5,6-tetrahydropyrimidin-1-ium-2-yl)benzenethiolate 9 (106mg,
0.5mmol) were used and refluxed for 3 h, giving 111mg
(0.308mmol) of crude free base. Afterwards, the obtained free
base was suspended in 2-propanol (10ml) followed by the add-
ition of methanesulfonic acid (22 ml, 0.34mmol) and stirring at
room temperature for 2 h. The reaction mixture was cooled over-
night, the resulting precipitate was filtered off crystallised from
ethanol/diethyl-ether mixture and dried at 75 C. Yield of pure
compound 15a as colourless solid was 117mg (47.6%), mp ¼
269–274 C. 1H NMR (300MHz, DMSO-d6) d¼ 9.94 (s, 2H, C(NH-
)2
þ), 9.62 (s, 1H, Ar-H), 8.60 (d, 1H, J¼ 1.5 Hz, Ar-H), 8.27 (d, 1H,
J¼ 8.5 Hz, Ar-H), 8.04 (d, 2H, J¼ 7.9 Hz, Ar-H), 7.88 (dd, 1H,
J¼ 1.9 Hz, J¼ 8.6 Hz, Ar-H), 7.69–7.56 (m, 3H, Ar-H), 3.57 (t, 4H,
J¼ 5.7 Hz, -CH2CH2CH2-), 2.32 (s, 3H, CH3SO3–), 2.06 (m, 2H,
-CH2CH2CH2-).
13C NMR (151MHz, DMSO-d6) d¼ 162.3 (s), 159.1
(s), 155.8 (s), 142.3 (s), 136.0 (s), 134.1 (s), 129.8 (d, 2C), 129.3 (d),
125.9 (d), 125.5 (s), 122.8 (d), 122.7 (d), 122.5 (d), 120.5 (d, 2C),
39.6 (q), 38.8 (t, 2C), 17.6 (t). LC-MS (ESI) m/z: 361.2 (MþHþ) calcd.
for free base M¼ 360.12. Analysis calcd. for C20H20N6O3S2  2H2O




According to the above-mentioned general method, 1-(4-chloro-
phenyl)-1H-1,2,3-triazole-4-carbaldehyde 6b (104mg, 0.5mmol)
and 2-amino-5-(3,4,5,6-tetrahydropyrimidin-1-ium-2-yl)benzene-
thiolate 9 (106mg, 0.5mmol) were used and refluxed for 2 h, giv-
ing 180mg (0.457mmol) of crude free base. Afterwards, the
obtained free base was suspended in ethanol (10ml) followed by
the addition of methanesulfonic acid (34ml, 0.52mmol) and stir-
ring at room temperature for 2 h. The reaction mixture was cooled
overnight, the resulting precipitate was filtered off and dried at
75 C. Yield of pure compound 15b as colourless solid was
143mg (58.4%), mp ¼ 288–293 C. 1H NMR (300MHz, DMSO-d6)
d¼ 9.99 (s, 2H, C(NH-)2þ), 9.71 (s, 1H, Ar-H), 8.61 (s, 1H, Ar-H), 8.27
(d, 1H, J¼ 8.5 Hz, Ar-H), 8.10 (d, 2H, J¼ 8.7 Hz, Ar-H), 7.87 (d, 1H,
J¼ 7.6 Hz, Ar-H), 7.74 (d, 2H, J¼ 8.7 Hz, Ar-H), 3.56 (t, 4H, J¼ 5.4 Hz,
-CH2CH2CH2-), 2.31 (s, 3H, CH3SO3
–), 2.04 (m, 2H, -CH2CH2CH2-).
13C NMR (151MHz, DMSO-d6) d¼ 162.0 (s), 159.0 (s), 155.7 (s),
142.3 (s), 134.8 (s), 134.1 (s), 133.6 (s), 129.7 (d, 2C), 125.8 (d),
125.6 (s), 122.7 (d), 122.6 (d), 122.2 (d, 2C), 39.5 (q), 38.8 (t, 2C),
17.6 (t). LC-MS (ESI) m/z: 395.2 (MþHþ) calcd. for free base
M¼ 394.08. Analysis calcd. for C20H19ClN6O3S2 (490.99): C, 48.92;
H, 3.90; N, 17.12%; Found C, 49.03; H, 3.66; N, 17.12%.
6-(3,4,5,6-Tetrahydropyrimidin-1-ium-2-yl)-2-[1-(4-methoxyphenyl)-
1H-1,2,3-triazole-4-yl]benzothiazole methanesulfonate (15c)
According to the above-mentioned general method, 1-(4-methoxy-
phenyl)-1H-1,2,3-triazole-4-carbaldehyde 6c (102mg, 0.5mmol)
and 2-amino-5-(3,4,5,6-tetrahydropyrimidin-1-ium-2-yl)benzene-
thiolate 9 (106mg, 0.5mmol) were used and refluxed for 2 h, giv-
ing 145mg (0.371mmol) of crude free base. Afterwards, the
obtained free base was suspended in ethanol (10ml) followed by
the addition of methanesulfonic acid (26 ml, 0.40mmol) and stir-
ring at room temperature for 2 h. The reaction mixture was cooled
overnight, the resulting precipitate was filtered off and dried at
75 C. Yield of pure compound 15c as colourless solid was 141mg
(55.3%), mp ¼ 261–265 C. 1H NMR (300MHz, DMSO-d6) d¼ 9.99
(s, 2H, C(NH-)2
þ), 9.57 (s, 1H, Ar-H), 8.60 (s, 1H, Ar-H), 8.26 (d, 1H,
J¼ 8.5 Hz, Ar-H), 7.95 (d, 2H, J¼ 8.7 Hz, Ar-H), 7.86 (d, 1H,
J¼ 8.3 Hz, Ar-H), 7.20 (d, 2H, J¼ 8.6 Hz, Ar-H), 3.87 (s, 3H, OCH3),
3.56 (m, 4H, -CH2CH2CH2-), 2.30 (s, 3H, CH3SO3
–), 2.04 (m, 2H,
-CH2CH2CH2-).
13C NMR (75MHz, DMSO-d6) d¼ 162.3, 159.7, 159.1,
155.7, 142.0, 134.1, 129.3, 125.7, 125.4, 122.7, 122.5, 122.3, 122.1
(2C), 114.8 (2C), 55.5, 38.8, 17.5. LC-MS (ESI) m/z: 391.2 (MþHþ)
calcd. for free base M¼ 390.13. Analysis calcd. for C21H22N6O4S2 




According to the above-mentioned general method, 1-benzyl-1H-
1,2,3-triazole-4-carbaldehyde 6d (94mg, 0.5mmol) and 2-amino-5-
(3,4,5,6-tetrahydropyrimidin-1-ium-2-yl)benzenethiolate 9 (106mg,
0.5mmol) were used and refluxed for 2 h, giving 106mg
(0.283mmol) of crude free base. Afterwards, the obtained free
base was suspended in 2-propanol (5ml) followed by the addition
of methanesulfonic acid (14ml, 0.21mmol) and stirring at room
temperature for 2 h. The reaction mixture was cooled overnight,
the resulting precipitate was filtered off and dried at 75 C. Yield
of pure compound 14d as colourless solid was 74mg (32.9%), mp
¼ 170–174 C. 1H NMR (300MHz, DMSO-d6) d¼ 9.94 (s, 2H, C(NH-
)2
þ), 9.01 (s, 1H, Ar-H), 8.56 (s, 1H, Ar-H), 8.21 (d, 1H, J¼ 8.4 Hz, Ar-
H), 7.85 (d, 1H, J¼ 7.9 Hz, Ar-H), 7.47–7.34 (m, 5H, Ar-H), 5.75 (s,
2H, -CH2-), 3.56 (m, 4H, -CH2CH2CH2-), 2.32 (s, 3H, CH3SO3
–), 2.05
(m, 2H, -CH2CH2CH2-).
13C NMR (151MHz, DMSO-d6) d¼ 162.7 (s),
159.1 (s), 155.8 (s), 141.6 (s), 135.3 (s), 134.0 (s), 128.7 (d, 2C), 128.3
(d), 128.0 (d, 2C), 125.8 (d), 125.5 (s), 124.6 (d), 122.8 (d), 122.7 (d),
53.4 (t), 38.9 (t, 2C), 17.6 (t). LC-MS (ESI) m/z: 375.2 (MþHþ) calcd.
for free base M¼ 374.13. Analysis calcd. for C21H22N6O4S2 




Human cell lines SW620 (colorectal adenocarcinoma, metastatic),
MCF-7 (human breast adenocarcinoma), CFPAC-1 (pancreatic
adenocarcinoma), HeLa (cervical carcinoma), and HFF-1 (human
foreskin fibroblasts) were obtained from the American Type
Culture Collection (ATCC). Cells were cultured in a humidified
atmosphere at 37 C with 5% CO2. As a growth medium,
Dulbecco’s modified Eagle medium (DMEM) was used with the
addition of foetal bovine serum (10%), L-glutamine (2mM), and
antibiotics: streptomycin (100mg/ml) and penicillin (100U/ml).
Proliferation assay
Cells were seeded onto 96-well microtiter plates at a seeding
density of 3000 cells/well for carcinoma cell lines, and 5000 cells/
well for normal human fibroblasts. The next day, cells were
treated with test agents at five different concentrations
(0.01–100 mM) and further incubated for 72 h. DMSO (solvent) was
tested for potential cytotoxic effect but it did not exceed 0.1%. 5-
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Fluorouracil (5-FU, 0.384M fluorouracilum, Pliva 500mg/10ml) dis-
solved in physiological solution was used as a positive control.
Following 72 h incubation, the MTT assay was performed and
measured absorbances were transformed into a percentage of cell
growth as described previously47. Results were obtained from
three independent experiments. IC50 values were calculated using
linear regression analysis (FORECAST option taking into account
the concentration range of two experimental points above and
below IC50).
Antitrypanosomal screening and cytotoxicity assays
Antitrypanosomal screening
Bloodstream form T. b. brucei (strain 221) were cultured in modi-
fied Iscove’s medium48 and assays were carried out in 96-well
microtiter plates (200 ll volumes) to determine the IC50 and IC90
values of each compound. Parasites growth was initiated at
2.5 104ml1, compounds were added at a range of concentra-
tions, and the plates were incubated at 37 C. Resazurin (20ll at
0.125mg ml1) was added after 48 h, the plates were incubated
for a further 16 h, and then read in a Spectramax plate reader,
and data analysed using GraphPad Prism. Each drug was tested
in triplicate.
L6 cell proliferation
For cytotoxicity assays, L6 cells (a rat myoblast line) were seeded
into 96-well microtiter plates at 1 104ml1 in 200 ll of the
growth medium, and different compound concentrations were
added. The plates were then incubated for 6 days at 37 C and
20ll resazurin was added to each well. After a further 8 h incuba-
tion, the fluorescence was determined using a Spectramax plate
reader, as outlined above.
DNA binding study
Compounds 11a, 11b, 12b, 14a, 14c and 15b were dissolved
(c¼ 5 103M for 12b, 14a, 14c, 15b, c¼ 4 103M for 11a,
11b) in water, while compounds 10b and 14b were dissolved
(c¼ 5 103M) in DMSO. These solutions were used for measure-
ments in an aqueous buffer (pH ¼ 7, sodium cacodylate buffer,
I¼ 0.05mol dm3). Polynucleotides were purchased as noted: poly
(dAdT)2 and calf thymus ctDNA (Sigma-Aldrich). Polynucleotides
were dissolved in Na-cacodylate buffer, I¼ 0.05mol dm3, pH ¼ 7.
The calf thymus ctDNA was additionally sonicated and filtered
through a 0.45mm filter49. Polynucleotide concentration was
determined spectroscopically50,51 as the concentration
of phosphates.
UV/vis measurements
The UV/Vis spectra were recorded on a Varian Cary 100 Bio spec-
trophotometer using 1 cm path quartz cuvettes. Calibration experi-
ments were performed at 25 C and pH ¼ 7 (I¼ 0.05mol dm3,
sodium cacodylate buffer). Absorption maxima and corresponding
molar extinction coefficients (e) of benzothiazole derivatives are
given in Table S1 (Supplementary material). Thermal melting
curves for DNA and their complexes with studied compounds
were determined as previously described by following the absorp-
tion change at 260 nm as a function of temperature. The absorb-
ance of the ligands was subtracted from every curve and the
absorbance scale was normalised. Tm values are the midpoints of
the transition curves determined from the maximum of the first
derivative and checked graphically by the tangent method. The
DTm values were calculated by subtracting Tm of the free nucleic
acid from Tm of the complex. Every DTm value reported here was
the average of at least two measurements. The error in DTm
is ±0.5 C.
Fluorimetric measurements
Fluorescence spectra were recorded on a Varian Cary Eclipse spec-
trophotometer at 25 C using appropriate 1 cm path quartz cuv-
ettes. Fluorimetric experiments were performed at pH ¼ 7
(I¼ 0.05mol dm3, sodium cacodylate buffer) by adding portions
of polynucleotide solution into the solution of the studied com-
pound. In fluorimetric experiments, an excitation wavelength of
kexc 300 nm was used to avoid the inner filter effect caused due
to increasing absorbance of the polynucleotide. Emissions were
determined in the range kem ¼ 350–650 nm. Values for Ks were
obtained by processing titration data using the Scatchard equa-
tion52. All had satisfactory correlation coefficients (>0.99).
CD measurements
CD spectra were recorded on a JASCO J815 spectrophotometer in
1 cm path quartz cuvettes. CD parameters: range ¼ 500–220 nm,
data pitch ¼ 2, standard sensitivity, scanning speed ¼ 200 nm/
min, accumulation ¼ 3–5. Titrations were performed at 25 C and
pH ¼ 7 (I¼ 0.05mol dm3, sodium cacodylate buffer). CD experi-
ments were done by adding portions of the compound stock
solution into the polynucleotide solution.
Results and discussion
Chemistry
The synthesis of novel 1,2,3-triazolyl linked 6-amidino substituted
benzothiazole derivatives 10a–10d, 11a–11d, 12a–12d, 13a–13d,
14a–14d, 15a–15d were synthesised according to the procedure
shown in Scheme 1.
4-(1,2,3-Triazol-1-yl)benzaldehyde derivatives (3a–3d) were pre-
pared by propargylation of 4-hydroxy benzaldehyde to give 4-O-
propargylated benzaldehyde (2). Intermediate 2 was then used as
a dipolarophile in copper(I)-catalysed Huisgen 1,3-dipolar cyclo-
addition with unsubstituted, p-chloro- and p-methoxy-substituted
phenyl azides to afford 3a–3d. With the aim of assessing the influ-
ence of the phenoxymethylene linker between the benzothiazole
and 1,2,3-triazole moieties on the anti-proliferative and antitrypa-
nosomal activities, the 1,2,3-triazole ring was introduced directly
(13a–13d, 14a–14d, and 15a–15d) to the benzothiazole ring as
displayed in Scheme 1. 1-Aryl-substituted 1,2,3-triazolyl aliphatic
alcohols (5a–5d) were prepared in excellent yields by using the
ultrasound-assisted reaction of propargyl alcohol and correspond-
ing aromatic azides with Cu(OAc)2. 1-Aryl-substituted 1,2,3-tri-
azole-carbaldehyde precursors (6a–6d) were subsequently
obtained by the Swern oxidation53.
Amidino-substituted 2-aminothiophenoles (7–9) were prepared
from 6-cyanobenzothiazole by the Pinner method, as previously
reported45,46. To study the influence of the type of the hydrophilic
amidino substituents, non-substituted amidino, imidazolino and
pyrimidino moieties were introduced at C-6 of benzothiazole scaf-
fold. Condensation of various amidino-substituted 2-aminothio-
phenoles (7–9) with 4-(1,2,3-triazol-1-yl)benzaldehyde precursors
(3a–3d) and 1,2,3-triazole-4-carbaldehyde precursors (6a–6d) was
carried out in acetic acid, followed by a simple acid-base reaction
step to afford the targeted amidino-substituted benzothiazole
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Table 1. The growth-inhibition effectsa in vitro of compounds 10a–10d, 11a–11d, 12a–12d, 13a–13d, 14a–14d, 15a–15d on human tumour cell lines and normal
fibroblasts.
Compd. R1 X R2
IC50 (lM)
SW620 CFPAC-1 MCF-7 HeLa HFF-1/WI-38c
10a –PhOCH2– 2.89 ± 0.03 3.34 ± 0.19 3.39 ± 1.17 2.89 ± 0.11 0.17 ± 0.04
10b –PhOCH2– 3.05 ± 0.82 1.76±.0.17 0.87 ± 0.18 1.24 ± 0.60 0.17 ± 0.13
10c –PhOCH2– 3.86 ± 0.29 3.45 ± 0.29 3.66 ± 1.49 2.87 ± 1.24 0.31 ± 0.08
10d –PhOCH2– 1.18 ± 0.18 5.15 ± 0.23 3.02 ± 0.98 1.77 ± 0.45 0.76 ± 0.18
11a –PhOCH2– 0.46 ± 0.03 0.45 ± 0.01 0.49 ± 0.01 0.57 ± 0.19 0.26 ± 0.02
11b –PhOCH2– 2.84 ± 0.19 3.09 ± 0.19 3.12 ± 0.36 2.61 ± 0.42 0.17 ± 0.09
11c –PhOCH2– 0.50 ± 0.16 2.06 ± 0.70 0.86 ± 0.97 2.53 ± 0.01 0.24 ± 0.13
11d –PhOCH2– 1.81 ± 0.55 1.21 ± 0.74 2.21 ± 1.17 1.40 ± 0.75 0.18 ± 0.02
12a –PhOCH2– 4.17 ± 0.28 3.98 ± 0.29 3.98 ± 0.04 2.95 ± 0.38 0.44 ± 0.03
12b –PhOCH2– 0.66 ± 0.21 3.55 ± 0.81 3.91 ± 1.19 2.81 ± 0.58 0.24 ± 0.09
12c –PhOCH2– 5.22 ± 1.24 3.31 ± 0.60 3.46 ± 0.45 2.64 ± 0.46 0.46 ± 0.27
12d –PhOCH2– 7.94 ± 2.58 23.42 ± 0.29 6.01 ± 0.53 8.60 ± 0.85 1.74 ± 0.29
13a 24.22 ± 4.31 26.58 ± 4.69 25.58 ± 3.15 7.77 ± 0.05 2.07 ± 0.13
13b 3.55 ± 0.85 3.17 ± 0.11 3.32 ± 0.01 2.74 ± 0.21 0.85 ± 0.05
13c 5.39 ± 0.41 5.23 ± 0.87 4.50 ± 0.43 3.64 ± 1.44 2.99 ± 1.17
13d 9.48 ± 0.29 25.93 ± 3.71 22.56 ± 0.91 14.90 ± 1.54 4.04 ± 1.35
14a 0.25 ± 0.16 0.45 ± 0.19 0.52 ± 0.26 0.67 ± 0.06 0.12 ± 0.01
(continued)
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mesylates (10a–10d, 11a–11d, 12a–12d, 13a–13d,
14a–14d, 15a–15d).
The structures of novel 6-amidino-substituted benzothiazoles
mesylates 10a–10d, 11a–11d, 12a–12d, 13a–13d, 14a–14d,
15a–15d were determined by using 1H and 13C NMR spectros-
copy, mass spectrometry, and elemental analysis (Materials and
methods section). The chemical shifts in the 1H and 13C NMR
spectra and the H–H coupling constants were consistent with the
proposed structures (Supplementary material).
Biological evaluations
Evaluation of antiproliferative activity
Antiproliferative evaluations of all synthesised compounds were
performed in vitro on human tumour cell lines, SW620 (colorectal
adenocarcinoma, metastatic), MCF-7 (human breast adenocarcin-
oma), CFPAC-1 (pancreatic adenocarcinoma), HeLa (cervical carcin-
oma), and non-tumour HFF-1 (human foreskin fibroblasts) cells. 5-
Fluorouracil (5-FU) was used as a reference drug. The results are
presented in Table 1.
It can be observed that the tested compounds exhibited strong
to moderate inhibitory activity towards tumour cell lines.
However, compounds with pronounced antiproliferative effects
affected the proliferation of the non-tumour HFF-1 cell line. The
type of amidino moiety at the benzothiazole influenced the anti-
proliferative activities (Figure 2). For example, among the 6-ami-
dino benzothiazoles, imidazolino-substituted derivatives 11a–11d
and 14a–14d showed the best inhibitory effects, particularly on
colorectal adenocarcinoma (SW620) and cervical carcinoma (HeLa)
cells. This correlates with our earlier findings for the benzimidazole
series41. Unsubstituted amidino-benzothiazole 13a–13d exhibited
up to 10-fold lower activities relative to their imidazolines
congeners 14a–14d. The cytostatic effects decreased in the fol-
lowing order: imidazoline>pyrimidine> non-substituted amidine.
The effect of the aromatic substituent at N-1 of 1,2,3-triazole
ring on antiproliferative activities varied depending on the type of
6-amidino moiety. In most cases, the p-chlorophenyl aromatic unit
contributed to the enhanced antiproliferative effects of 10b, 12b,
13b, and 15b, except in the case of imidazolino-benzothiazoles. In
benzothiazole imidazolines, the unsubstituted phenyl ring in 11a
and 14a had the highest influence on inhibitory activity. The
2-imidazolino-substituted derivative 14a exhibited the highest
activity on SW620 (IC50 ¼ 0.25 mM) and CFPAC-1 (IC50 ¼ 0.45 mM)
cell lines, while 14c, which contains a p-methoxyphenyl ring, was
the most potent against HeLa cells (IC50 ¼ 0.38 mM). The benzo-
thiazole imidazoline 11a was the most active representative of
this class (IC50 ¼ 0.49mM) against MCF-7 cells. Comparison of the
effect of the aryl substituents at the N-1 position of the 1,2,3-tri-
azole ring on activity revealed that, among 2-imidazolino-substi-
tuted derivatives, phenyl and p-methoxyphenyl substituents
caused better potencies than p-chlorophenyl and benzyl
substituents.
The introduction of a phenoxymethylene linker improved the
activity of the resulting 10a–10d and 12a–12d up to 8-fold, rela-
tive to the corresponding benzothiazoles directly connected to
1,2,3-triazole in 13a–13d and 15a–15d. In contrast, with imidazo-
lino-benzothiazoles, direct fusion of benzothiazole to 1,2,3-triazole
in 14a–14d enhanced antiproliferative activity compared to
11a–11d, which contained a phenoxymethylene spacer.
Evaluation of antitrypanosomal activity
Preliminary screening of 2-arylbenzimidazole amidines 6a–6c,
7a–7c, 8, 14a–18a, 14b–18b, and 14c–18c against bloodstream-
Table 1. Continued.
Compd. R1 X R2
IC50 (lM)
SW620 CFPAC-1 MCF-7 HeLa HFF-1/WI-38c
14b 0.35 ± 0.13 2.42 ± 0.06 1.77 ± 0.18 0.48 ± 0.01 0.36 ± 0.18
14c 0.36 ± 0.09 0.48 ± 0.03 0.54 ± 0.01 0.38 ± 0.10 0.18 ± 0.01
14d 0.85 ± 0.61 8.71 ± 3.74 1.76 ± 1.17 0.82 ± 0.01 0.11 ± 0.01
15a 4.15 ± 1.58 37.57 ± 4.58 8.31 ± 0.12 7.62 ± 0.84 0.53 ± 0.10
15b 0.89 ± 0.31 0.71 ± 0.17 2.10 ± 1.09 2.27 ± 0.08 0.74 ± 0.05
15c 4.07 ± 1.06 4.74 ± 0.14 4.28 ± 0.06 4.30 ± 0.41 1.33 ± 0.17
15d 31.86 ± 8.38 49.89 ± 12.5 40.58 ± 10.6 30.99 ± 4.50 18.93 ± 0.19
5-FUb 6.4 ± 0.22 6.45 ± 0.66 0.09 ± 0.01 47.52 ± 1.93 0.94c
a50% inhibitory concentration or compound concentration required to inhibit tumour cell proliferation by 50%; bcontrol substance 5-fluorouracil; cWI-38 fibroblast
cell line.
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form T. brucei in vitro was performed at a range of concentrations
to select compounds with the highest inhibition for further evalu-
ation (Table S1, Supplementary material). Thus, compounds,
10a–10c, 11a–11d, 12b, 12c, 13a, 13b, 14a–14d, and 15b, were
submitted for more detailed evaluation and the concentrations
that inhibited growth by 50% (IC50) and 90% (IC90) were deter-
mined (Table 2). Nifurtimox was included as a reference drug.
Cytotoxicity was assessed using the rat myoblast cell line L6.
All tested compounds showed potent activity against T. brucei
with IC50 values ranging from 0.09 to 3.68mM and IC90s ranging
from 0.12 to 8.66mM, more potent than the front-line drug nifurti-
mox. We investigated the influence of unsubstituted and cyclic
amidino moiety, and aromatic substituent attached to the N-1 of
the 1,2,3-triazole ring on antitrypanosomal activity (Figure 2).
Similar to antiproliferative evaluations, imidazolino-substituted
benzothiazoles 11a–11c and 14a–14c exhibited the best anti-try-
panosomal activity, with the p-chlorophenyl analogue 11b being
the most promising compound (IC50 ¼ 0.09mM, IC90 ¼ 0.12mM).
With the exception of compounds 11d and 14d, which contain
the N-1-benzyl-1,2,3-triazolyl moiety, benzothiazole imidazolines
11a–11c and 14a–14c showed potency in submicromolar concen-
trations, with IC90 in the range of 0.12–0.53 mM. However, these
compounds were cytotoxic to rat myoblast cell line L6 (IC50 >
0.2 mM). Some selectivity (SI ¼ 1.8–6.9) was observed for benzo-
thiazole pyrimidines and non-substituted amidines.
Replacement of the phenoxymethylene linker in 10a–10d,
11a–11d, and 12a–12d with a direct fusion of benzothiazole to
1,2,3-triazole in 13a–13d, 14a–14d, and 15a–15d reduced antitry-
panosomal activity against bloodstream-form T. brucei.
Furthermore, the introduction of an electron-withdrawing p-chloro
substituent in 10b–15b improved the inhibitory effect. The rela-
tionship between the type of aromatic substituents and their
activities revealed that antitrypanosomal effects decreased in the
following order: p-ClPh>p-OCH3Ph> Ph> Bn.
DNA binding study
As a carrier of genetic information and a great influence on vital
processes in the cell, DNA is the main target of a large number of
drugs with anticancer and antiprotozoal activity55–57. Among
them, anthracyclines that target DNA topoisomerase II cause
highly lethal DNA breaks in proliferating cancer cells, while some
drugs, such as quinacrine, with a long history of clinical use in the
treatment of malaria, modulate cellular pathways that lead to cel-
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Scheme 1. Reagents and reaction conditions: (i): propargyl bromide, K2CO3, EtOH, reflux; (ii): corresponding azides, CuSO4, Cu(0), DMF, t-BuOH:H2O ¼ 1:1, 80 C; (iii):
corresponding azides, Cu(OAc)2, MeOH, 80 C, US, 1.5 h; (iv): (COCl)2, DMSO, Et3N, CH2Cl2, 78 C to rt 45min; (v): (a) corresponding thiolates 7–9 and aldehydes
3a–3d, 6a–6d, HOAc, reflux 2–4 h then NaOH (aq) pH 10–12, (b) corresponding amidine free bases, EtOH or i-PrOH, 1.1 eq. MSA, 2 h, rt.
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With the aim of investigating possible mechanisms of antiproli-
ferative and antitrypanosomal action, we examined the DNA inter-
actions of compounds that had exhibited the most potent
submicromolar activities, 10b, 11a, 11b, 12b, 14–14c, and 15b.
The study was performed with a double-stranded (ds-) poly-
nucleotide, calf-thymus (ct)DNA which represents a classical
B-helix consisting of 58% AT base pairs (and 42% GC base pairs).
Titration with ctDNA yielded fluorescence quenching of the
studied compounds (Figure 3, Table 3, Figures S19–S26,
Supporting material). It can be observed that the addition of
ctDNA caused a small redshift (D ¼ 1–5 nm) of emission maxima.
The binding constants, Ks obtained by processing of fluorimet-
ric titration data with the Scatchard equation52 are summarised in
Table 3. Interestingly, the 6-amidinobenzothiazoles 10b, 11a, 11b,
and 12b, which have a phenoxymethylene linker, showed higher
binding affinities towards ds-DNA than compounds 14a–14c and
15b, which lack the linker. Non-covalent interaction of small mole-
cules with DNA can affect the thermal stability of the double helix,
which results in either an increase or decrease of the melting tem-
perature (Tm)
58. The intercalative mode of binding usually results
in an increased Tm value, while groove binding molecules can sta-
bilise or destabilise the double-stranded structure, resulting in
increased or decreased Tm values, respectively. The majority of
studied compounds showed a small stabilisation effect of ctDNA
(58% AT). Moreover, all 6-amidinobenzothiazoles stabilised DNA
consisted of only AT sequences. The best stabilisation effects of
AT-DNA were observed for 11a, 14c, and 15b (Table 4).
The formation of complexes between small molecules and
DNA can be monitored using circular dichroism (CD) spectroscopy.
A mutual orientation of achiral small molecule and polynucleotide
chiral axis, which results in an induced CD (ICD) signal, could give
us additional information about modes of interaction59,60. Hence,
the most reliable insight into modes of interaction between small
molecules and DNA can be retrieved at wavelength area,
k> 300 nm, where ligands possess UV/Vis spectra, while DNA
does not.
The addition of studied compounds to ctDNA resulted in a
decreased intensity of the CD band of ds-polynucleotide, ctDNA
(Figure 4, Figures S31 and S32).
Furthermore, compounds 12b and 15b exhibited positive
induced CD spectra (ICD) with ctDNA around 300 nm and 345 nm,
respectively, supporting a minor groove binding mode to
ctDNA39,40,61,62. Similar changes in CD spectra were noticed for
classical minor groove binders like DAPI or Hoechst 3325844.
The addition of compound 11a to a ctDNA solution resulted in
the appearance of a bisignate signal with maxima at 317 and
360 nm. Such change suggests the binding of 11a in the form of
a dimer within the minor groove (Figure 4)62.
In the titration of ctDNA with 10b and 11b, a small negative
ICD signal appeared, while 14a–14c caused the small positive ICD
signal upon binding to ctDNA (Figure 4, Figures S31 and S32).
Such changes, whether small negative, or positive, point to an
intercalative way of binding. This is additionally supported by
thermal stabilisation of ctDNA and/or AT-DNA (Table 4), as well as
binding constants of 1 mM (Table 3), which were observed with
the majority of studied benzothiazoles.
The positive sign of the ICD band observed with 14a–14c sug-
gests that the long axis of the benzothiazole moiety is approxi-
mately perpendicular to the long axis of the basepair pocket, but
still in the plane with the adjacent base pairs. The negative sign
of the ICD band found for 10b and 11b indicates that the transi-
tion moment of the ligand is oriented “parallel” to the long axis
of adjacent base pairs42,63.
At higher ratios, r 0.3, a big decrease of intensity of the CD
bands and strong negative ICD spectra observed with 14a–14c
can be attributed to non-specific aggregation of non-intercalated
molecules along the DNA backbone, possibly within
major grooves43.
Conclusions
The 6-amidinobenzothiazoles 10a–10d, 11a–11d, 12a–12d,
13a–13d, 14a–14d, and 15a–15d, containing distributed highly
hydrophilic cationic moieties and hydrophobic aromatic compo-
nents were designed and synthesised with the aim of performing
antiproliferative and antiprotozoal evaluations. The antiproliferative
assessment showed that imidazoline moieties improved the
growth-inhibitory effects of 11a–11d and 14a–14d and that ben-
zothiazole directly connected to the 1,2,3-triazole in 14a–14d add-
itionally increased inhibitory activity. Thus, benzothiazole
imidazolines 11a, 14a and 14c showed the most pronounced
inhibitory effects on all the tumour cell lines studied (11a: IC50 ¼
0.49 mM, MCF-7; 14a: IC50 ¼ 0.25mM, SW620, IC50 ¼ 0.45 mM,
CFPAC-1; 14c: IC50 ¼ 0.38 mM, HeLa). However, 6-amidinobenzothia-
zoles also affected the proliferation of the non-tumour HFF-1
cell line.
Similarly, the antitrypanosomal evaluations showed that benzo-
thiazole imidazolines 11a–11c and 14a–14c exhibited the best
potency, with values that paralleled antiproliferative activity.
Figure 2. Structure–activity relationship for antiproliferative and antitrypanosomal activity of the 2-arylbenzothiazole amidines.
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Table 2. Antitrypanosomal activitya of compounds 10a–10c, 11a–11d, 12b–12c, 13a–13b, 14a–14d and 15b against Trypanosoma brucei (strain 221).
Compd. R1 X R2
T. brucei
L6 cells SIc
IC50 (mM) IC90 (mM) IC50 (mM) IC50 (L6/Tb)
10a –PhOCH2– 1.17 ± 0.10 1.45 ± 0.11 <2.0
10b –PhOCH2– 0.54 ± 0.13 0.81 ± 0.04 1.46 ± 0.45 2.7
10c –PhOCH2– 1.00 ± 0.07 1.26 ± 0.02 <2.0
11a –PhOCH2– 0.23 ± 0.02 0.28 ± 0.03 <0.2
11b –PhOCH2– 0.09 ± 0.02 0.12 ± 0.03 <2.0
11c –PhOCH2– 0.19 ± 0.04 0.23 ± 0.05 <2.0
11d –PhOCH2– 1.09 ± 0.02 1.30 ± 0.02 <0.2
12b –PhOCH2– 0.91 ± 0.08 1.19 ± 0.02 2.32 ± 0.18 2.5
12c –PhOCH2– 0.90 ± 0.05 1.18 ± 0.02 2.92 ± 0.26 3.2
13a 2.02 ± 0.10 2.52 ± 0.34 7.97 ± 0.96 3.9
13b 0.67 ± 0.07 1.02 ± 0.02 2.69 ± 0.42 4.0
14a 0.40 ± 0.02 0.53 ± 0.03 <2.0
14b 0.32 ± 0.06 0.48 ± 0.02 <2.0
14c 0.31 ± 0.02 0.49 ± 0.01 <2.0
14d 3.68 ± 0.22 8.66 ± 0.20 6.64 ± 0.53 1.8
15b 1.12 ± 0.23 3.84 ± 0.65 7.69 ± 0.16 6.9
Nifurtimoxb 2.0 ± 0.24b
aIn vitro activity against bloodstream form T. brucei expressed as the concentration that inhibited growth by 50% (IC50) and 90% (IC90). Data are the mean of tripli-
cate experiments ± SEM. bTaken from Wilkinson et al.54. cSelectivity index, SI ¼ [IC50 L6 cells]/[IC50 T. brucei].
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In contrast to antitumor results, a direct fusion of benzothiazole
to 1,2,3-triazole decreased antitrypanosomal activity. 6-
Imidazolinobenzothiazole 11b containing p-chlorophenyl at N-1 of
1,2,3-triazole displayed the highest antitrypanosomal potency (IC50
¼ 0.09 mM, IC90 ¼ 0.12 mM). UV–Vis and CD spectroscopy, as well
as thermal denaturation assays, indicated the binding affinities of
6-amidinobenzothiazoles towards ctDNA. Strong positive ICD
bands supported minor groove binding, as the dominant binding
mode of 11a, 12b and 15b, while small negative and positive ICD
signals identified intercalation, as the predominant binding mode
of 10b and 11b and 14a–14c.
We may conclude that the 6-amidinobenzothiazoles, which
exhibit antiproliferative and antitrypanosomal potency in the sub-
micromolar range and DNA interacting properties, warrant further
structural optimisation to reduce their toxicity against normal
cells, with the aim of developing novel antitumor or/and anti-
HAT agents.
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